SARS-CoV-2 vaccines in development

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives

McNulty, M. J., Silberstein, D. Z., Kuhn, B. T., Padgett, H. S., Nandi, S., McDonald, K. A., & Cross, C. E. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.030 · Cited by 16

The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19

García‐Escobar, A., Jiménez‐Valero, S., Galeote, G., y, A. J.-R., García‐Rodríguez, J., & Moreno, R. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10066-6 · Cited by 16

Micronutrients and phytochemicals against COVID-19: Mechanism and molecular targets

Bellik, Y., Bachir‐bey, M., Fatmi, W., Kouidri, M., Souagui, Y., & Selles, S. M. A. (2020) · Annals of Phytomedicine An International Journal · doi:10.21276/ap.2020.9.2.3 · Cited by 15

Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease

Hajbabaie, R., Harper, M. T., & Rahman, T. (2021) · Molecules · doi:10.3390/molecules26041134 · Cited by 16

Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients

Dwyer, C. J., Cloud, C. A., Wang, C., Heidt, P., Chakraborty, P., Duke, T., McGue, S. R., Jeffcoat, B., Dunne, J., Johnson, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102489 · Cited by 15

Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination

Davenport, B., Morrison, T. E., Kedl, R. M., & Klarquist, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100195 · Cited by 15

Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1

Alluhaybi, K. A., Alharbi, R. H., Alhabbab, R. Y., Aljehani, N. D., Alamri, S. S., Basabrain, M. A., Alharbi, R., Abdulaal, W. H., Alfaleh, M. A., Tamming, L. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080852 · Cited by 16

Know your enemy and know yourself – the case of SARS-CoV-2 host factors

Lee, W. S., Yousefi, M., Yan, B., Yong, C. L., & Ooi, Y. S. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.08.007 · Cited by 16

Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential

Kubik, S., Arrigo, N., Bonet, J., & Xu, Z. (2021) · Viruses · doi:10.3390/v13112114 · Cited by 16

SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters 1

Zhou, B., Zhou, R., Chan, J. F., Zeng, J., Zhang, Q., Yuan, S., Liu, L., Robinot, R., Shan, S., Liu, N., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2245921 · Cited by 22

Delivery of Circular mRNA via Degradable Lipid Nanoparticles against SARS-CoV-2 Delta VariantPreprint

Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Hou, Q., Gao, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.12.491597 · Cited by 16

Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern

Wang, Q., Nair, M. S., Anang, S., Zhang, S., Nguyen, H., Huang, Y., Liu, L., Ho, D. D., & Sodroski, J. G. (2021) · iScience · doi:10.1016/j.isci.2021.103393 · Cited by 15

SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation

Ataya, F. S., Alamro, A. A., Alghamdi, A. A., & Fouad, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-15979-6 · Cited by 15

Toward superhuman SARS-CoV-2 immunity?

Burton, D. R., & Topol, E. J. (2020) · Nature Medicine · doi:10.1038/s41591-020-01180-x · Cited by 15

The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants

Damasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 15

SARS-CoV2 Vaccination Adverse Events Trend in Italy: A Retrospective Interpretation of the Last Year (December 2020–September 2021)

Fazio, N. D., Delogu, G., Bertozzi, G., Fineschi, V., & Frati, P. (2022) · Vaccines · doi:10.3390/vaccines10020216 · Cited by 15

Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern

McMillan, C. L. D., Azuar, A., Choo, J. J. Y., Modhiran, N., Amarilla, A. A., Isaacs, A., Honeyman, K. E., Cheung, S. T. M., Liang, B., Wurm, M. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10040578 · Cited by 15

Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques

Tong, D., Zhang, M., Yang, Y., Xia, H., Tong, H., Zhang, H., Zeng, W., Liu, M., Wu, Y. L., Ma, H., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac020 · Cited by 14

Mucosal delivery of nanovaccine strategy against COVID-19 and its variants

Lee, J., & Khang, D. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.022 · Cited by 15

Interface-Based Design of High-Affinity Affibody Ligands for the Purification of RBD from Spike Proteins

Song, S., & Shi, Q. (2023) · Molecules · doi:10.3390/molecules28176358 · Cited by 14

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Ringe, R. P., Colin, P., Ozorowski, G., Allen, J. D., Yasmeen, A., Seabright, G. E., Lee, J. H., Antanasijevic, A., Rantalainen, K. I., Ketas, T. J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011601 · Cited by 15

A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4 + and CD8 + T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection

Zayou, L., Prakash, S., Dhanushkodi, N. R., Quadiri, A., Ibraim, I. C., Singer, M., Salem, A., Shaik, A. M., Suzer, B., Chilukuri, A., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01096-23 · Cited by 15

Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants

Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 16

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective

Zhang, Y., Chamblee, M., Xu, J., Qu, P., Shamseldin, M. M., Yoo, S. J., Misny, J., Thongpan, I., Mahesh, K. C., Hall, J. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49443-2 · Cited by 15

Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms

Guo, C. M., Chai, X., Baerlike, M., Liu, Y., Wang, Y., Shao, F., Huang, Q., Zhang, W., Cen, S., Dong, Y., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.09.002 · Cited by 16

Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time?

Krammer, F. (2020) · Med · doi:10.1016/j.medj.2020.11.004 · Cited by 15

Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination

Afarid, M., & Sanie‐Jahromi, F. (2021) · Stem Cells International · doi:10.1155/2021/6666370 · Cited by 15

A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic

Chrysostomou, A. C., Vrancken, B., Koumbaris, G., Themistokleous, G., Aristokleous, A., Masia, C., Eleftheriou, C., Iοannou, C., Stylianou, D. C., Ioannides, M., et al. (2021) · Viruses · doi:10.3390/v13061098 · Cited by 15

A Brief Overview of COVID-19 Vaccines

Farhud, D. D., & Zokaei, S. (2021) · Iranian Journal of Public Health · doi:10.18502/ijph.v50i7.6656 · Cited by 15

Imaging and visualizing SARS-CoV-2 in a new era for structural biology

Leigh, K. E., & Modis, Y. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0019 · Cited by 17

Inhibition of Prostaglandin F2α Receptors Exaggerates HCl-Induced Lung Inflammation in Mice

Maehara, T., & Fujimori, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312843 · Cited by 15

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Dodaran, M. S., Banihashemi, S. R., Es‐haghi, A., Mehrabadi, M. H. F., Noofeli, M., Mokarram, A. R., Mokhberalsafa, L., Sadeghi, F., Ranjbar, A., Ansarifar, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020455 · Cited by 15

CRESSP: a comprehensive pipeline for prediction of immunopathogenic SARS-CoV-2 epitopes using structural properties of proteins

An, H., Eun, M., Yi, J., & Park, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac056 · Cited by 16

Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 InfectionPreprint

Rao, Y., Wang, T., Qin, C., Espinosa, B., Liu, Q., Ekanayake, A. I., Zhao, J. X., Savas, A. C., Zhang, S. J., Zarinfar, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429959 · Cited by 15

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

Kim, Y., Zheng, X., Eschke, K., Chaudhry, M. Z., Bertoglio, F., Tomić, A., Krmpotić, A., Hoffmann, M., Bar-On, Y., Boehme, J., et al. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00814-5 · Cited by 14

Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic

Whittaker, C., Barnsley, G., Mesa, D. O., Cox, V. A., Laydon, D. J., Tan, C. W., Zhu, F., Johnson, R., Doohan, P., Whittles, L. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63399-x · Cited by 13

Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2

Fernández‐Lázaro, D., Fernandez-Lazaro, C. I., Mielgo‐Ayuso, J., Adams, D. P., Garcı́a, J. L., Gonzalez-Bernal, J. J., & González‐Gross, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698672 · Cited by 14

SARS-CoV-2 Vaccines and the Skin

Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.07.028 · Cited by 14

Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines

Lee, Y., Hong, S., Park, H., Lee, H., Hwang, J.-Y., Kim, S. Y., Park, J. W., Choi, K.-S., Seong, J. K., Park, S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.732450 · Cited by 14

A pandemia de COVID-19 em Portugal: Evolução, Vacinação e Farmacovigilância

Ferreira‐da‐Silva, R., Macedo, M., Conceição, J., & Escola Superior de Saúde Cruz Vermelha Portuguesa, A. T. (2022) · revistamultidisciplinar com · doi:10.23882/rmd.22090 · Cited by 14

Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities

Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15

Fucosylated N-glycans as early biomarkers of COVID-19 severity

Paton, B., Herrero, P., Peraire, J., del Pino, A., Chafino, S., Martínez‐Picado, J., Gómez-Bertomeu, F., Rull, A., Canela-Canela, N., & Suárez, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204661 · Cited by 13

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose

Beaudoin-Bussières, G., Tauzin, A., Dionne, K., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Levade, I., Alfadhli, L., Bo, Y., Bazin, R., et al. (2023) · Viruses · doi:10.3390/v15061274 · Cited by 15

Factors associated with stroke after COVID-19 vaccination: a statewide analysis

Nahab, F. B., Bayakly, R. A., Sexton, M. E., Lemuel-Clarke, M., Henríquez, L., Rangaraju, S., & Ido, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1199745 · Cited by 14

Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers—Orchestra Project

Violán, C., Carrasco-Ribelles, L. A., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., Reinkemeyer, C., Thi, T. G. L., Liviero, F., Scapellato, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11081340 · Cited by 14

Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine

Sheehan, J., Ardizzone, C. M., Khanna, M., Trauth, A. J., Hagensee, M. E., & Ramsay, A. J. (2023) · Vaccines · doi:10.3390/vaccines11111720 · Cited by 14

Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants

Yang, Z.-S., Li, T.-S., Huang, Y.-S., Chang, C., & Chien, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-53111-2 · Cited by 14

An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome–Coronavirus

Kathiravan, M. K., Radhakrishnan, S., Namasivayam, V., & Senthilkumar, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.637550 · Cited by 13

Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice

Kim, K., Bhatnagar, N., Jeeva, S., Oh, J., Park, B. R., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9040316 · Cited by 15

Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo

Yadav, N., Vishwakarma, P., Khatri, R., Siddqui, G., Awasthi, A., Ahmed, S., & Samal, S. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104843 · Cited by 14

Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia

Alhazmi, A., Alamer, E., Abdelwahab, S. İ., Khamjan, N. A., Hamami, A., Haddad, M. A., Darraj, M. A., Hashem, A. M., & Algaissi, A. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312451 · Cited by 15

The Evolution and Disparities of Online Attitudes Toward COVID-19 Vaccines: Year-long Longitudinal and Cross-sectional Study

Zhang, C., Xu, S., Li, Z., Liu, G., Dai, D., & Dong, C. (2021) · Journal of Medical Internet Research · doi:10.2196/32394 · Cited by 14

Solid Dosage Forms of Biopharmaceuticals in Drug Delivery Systems Using Sustainable Strategies

Costa, C., Casimiro, T., Corvo, M. L., & Aguiar‐Ricardo, A. (2021) · Molecules · doi:10.3390/molecules26247653 · Cited by 18

Erythro-VLPs: Anchoring SARS-CoV-2 spike proteins in erythrocyte liposomes

Himbert, S., Gastaldo, I. P., Ahmed, R., Pomier, K. M., Cowbrough, B., Jahagirdar, D., Ros, S., Juhasz, J., Stöver, H. D. H., Ortega, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263671 · Cited by 15

Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review

Sanyaolu, A. O., Okorie, C., Marinkovic, A., Prakash, S., Williams, M., Haider, N., Mangat, J., Hosein, Z., Balendra, V., Abbasi, A. F., et al. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221097559 · Cited by 14

A Review on COVID-19 Vaccinations

Garg, K., Talwar, D., Mahajan, S. N., Karim, S., Prajapati, K., Patel, S., & Garg, B. (2022) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_280_21 · Cited by 14

Epidemiological aspects of headache after different types of COVID ‐19 vaccines: An online survey

Magdy, R., Khedr, D. M., Yacoub, O., Attia, A., Abdelrahman, M. A., & Mekkawy, D. (2022) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14374 · Cited by 13

Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs

Nwabufo, C. K., & Bendayan, R. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.005 · Cited by 14

Adaptation‐Proof SARS‐CoV‐2 Vaccine Design

Vishweshwaraiah, Y. L., Hnath, B., Rackley, B., Wang, J., Gontu, A., Chandler, M. R., Afonin, K. A., Kuchipudi, S. V., Christensen, N. D., Yennawar, N. H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206055 · Cited by 12

Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro)

Pereira, F., Bedda, L., Tammam, M. A., Alabdullah, A. K., Arafa, R. K., & El‐Demerdash, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2217513 · Cited by 14

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

Carreño, J. M., Mendu, D. R., Simon, V. R., Shariff, M. A., Singh, G., Menon, V. P., & Krammer, F. (2021) · iScience · doi:10.1016/j.isci.2021.102937 · Cited by 12

Genetic Diversity and Evolution of the Biological Features of the Pandemic SARS-CoV-2

Nikonova, A. A., Файзулоев, Е. Б., Gracheva, A. V., Isakov, I. Y., & Зверев, В. В. (2021) · Acta Naturae · doi:10.32607/actanaturae.11337 · Cited by 14

COVID-19: The Pseudo-Environment and the Need for a Paradigm Change

Stein, R. A., Ometa, O., & Broker, T. R. (2021) · GERMS · doi:10.18683/germs.2021.1283 · Cited by 16

Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination

Kim, N., Minn, D., Park, S., Roh, E. Y., Yoon, J. H., Park, H., & Shin, S. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e158 · Cited by 13

Research Progress in the Treatment of Complications and Sequelae of COVID-19

Wang, J., Zhu, K., Xue, Y., Wen, G., & Tao, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.757605 · Cited by 13

Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management

Chavda, V. P., Patel, A., Vora, L. K., Apostolopoulos, V., & Uhal, B. D. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110076 · Cited by 13

RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge

Wong, T. Y., Russ, B. P., Lee, K. S., Miller, O. A., Kang, J. H., Cooper, M., Winters, M. T., Rodriguez‐Aponte, S. A., Dalvie, N. C., Johnston, R. S., et al. (2022) · mSphere · doi:10.1128/msphere.00243-22 · Cited by 12

Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development

Wang, Z., Huang, R., Han, B. R., Wu, F., Sun, Z., Li, G., Zhang, W., Zhao, Z., & Liu, X. (2022) · Chinese Neurosurgical Journal · doi:10.1186/s41016-022-00301-4 · Cited by 13

Lung T cell response in COVID-19

Shakiba, M. H., Gemünd, I. D., Beyer, M., & Bonaguro, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1108716 · Cited by 13

Achievements of COVID-19 vaccination programs: Taiwanese perspective

Sheng, W., Hsieh, S., & Chang, S. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.04.017 · Cited by 13

Proximal myopathy: causes and associated conditions

Rao, A., Nawaz, I., Arbi, F. M., & Ishtiaq, R. (2022) · Discoveries · doi:10.15190/d.2022.19 · Cited by 13

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor

Chia, W. N., Tan, C. W., Tan, A. W. K., Young, B. E., Starr, T. N., López, E., Fibriansah, G., Barr, J. A., Cheng, S. M. S., Yeoh, A. Y.-Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3470 · Cited by 13

Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis

Hua, T., Fan, R., Fan, Y., & Chen, F. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2357424 · Cited by 10

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations

Qian, G., Gao, C., Zhang, M., Chen, Y., & Xie, L. (2024) · Vaccines · doi:10.3390/vaccines12060579 · Cited by 13

Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays

Hu, Z., López-Muñoz, A. D., Košík, I., Li, T., Callahan, V., Brooks, K., Yee, D. S., Hollý, J., Santos, J. J. D. S., Brant, A. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310421121 · Cited by 11

Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics

Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34577 · Cited by 13

Exploring Future Pandemic Preparedness Through the Development of Preventive Vaccine Platforms and the Key Roles of International Organizations in a Global Health Crisis

Jeon, J.-H., & Kim, E. Y. (2025) · Vaccines · doi:10.3390/vaccines13010056 · Cited by 15

SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion

Ruan, W., Gao, P., Qu, X., Jiang, J., Zhao, Z., Qiao, S., Zhang, H., Yang, T., Li, D., Du, P., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105634 · Cited by 13

Harnessing biomaterials for therapeutic strategies against COVID-19

Colombani, T., Rogers, Z. J., Eggermont, L. J., & Bencherif, S. A. (2021) · Emergent Materials · doi:10.1007/s42247-021-00171-z · Cited by 13

SARS-CoV-2 vaccines — the biggest medical research project of the 21st century

Kurup, D., & Schnell, M. J. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.04.008 · Cited by 13

Droplet-capturing coatings on environmental surfaces based on cosmetic ingredients

Yu, Z., Kadir, M., Liu, Y., & Huang, J. (2021) · Chem · doi:10.1016/j.chempr.2021.05.017 · Cited by 13

An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS‐CoV‐2 Activity

Shagufta, S., & Ahmad, I. (2021) · ChemistrySelect · doi:10.1002/slct.202103301 · Cited by 12

Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules

Gedefaw, L., Ullah, S., Lee, T. M. H., Yip, S. P., & Huang, C. (2021) · Biomedicines · doi:10.3390/biomedicines9121823 · Cited by 13

Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library

Mendoza-Salazar, I., Gómez-Castellano, K., González‐González, E., Gamboa-Suasnavart, R. A., Rodríguez-Luna, S. D., Santiago-Casas, G., Cortés-Paniagua, M. I., Pérez‐Tapia, S. M., & Almagro, J. C. (2022) · Antibodies · doi:10.3390/antib11010013 · Cited by 13

What’s Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics

Das, R., Kanjilal, P., Medeiros, J., & Thayumanavan, S. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00058 · Cited by 13

The Promises of Speeding Up: Changes in Requirements for Animal Studies and Alternatives during COVID-19 Vaccine Approval–A Case Study

Ritskes-Hoitinga, M. J., Barella, Y., & Kleinhout‐Vliek, T. (2022) · Animals · doi:10.3390/ani12131735 · Cited by 13

Durability of SARS-CoV-2 Specific IgG Antibody Responses Following Two Doses of Match and Mixed COVID-19 Vaccines Regimens in Saudi Population

Mubarak, A., Almutairi, S. M., Al-Dhabbah, A. D., Aldabas, S. Y., Bhat, R., Alqoufail, M. M., Abdel-Maksoud, M. A., Almanaa, T. N., Farrag, M. A., & Alturaiki, W. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s369769 · Cited by 14

Vaccine Development for Human Leishmaniasis

Clímaco, M. D. C., Kraemer, L. R., & Fujiwara, R. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-24355-4_14 · Cited by 13

Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity

Sivasankar, C., Hewawaduge, C., & Lee, J. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.015 · Cited by 15

Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals

Kim, H., Seiler, P., Jones, J. C., Ridout, G., Camp, K. P., Fabrizio, T. P., Jeevan, T., Miller, L. A., Throm, R. E., Ferrara, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8040684 · Cited by 13

Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms

Bayat, M., Asemani, Y., & Najafi, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107679 · Cited by 15

Production of full-length SARS-CoV-2 nucleocapsid protein from Escherichia coli optimized by native hydrophobic interaction chromatography hyphenated to multi-angle light scattering detection

Vos, J. D., Aguilar, P. P., Köppl, C., Fischer, A., Grünwald‐Gruber, C., Duerkop, M., Klausberger, M., Mairhofer, J., Striedner, G., Cserjan‐Puschmann, M., et al. (2021) · Talanta · doi:10.1016/j.talanta.2021.122691 · Cited by 13

Gene-Delivery Ability of New Hydrogenated and Partially Fluorinated Gemini bispyridinium Surfactants with Six Methylene Spacers

Massa, M., Rivara, M., Donofrío, G., Cristofolini, L., Peracchia, E., Compari, C., Bacciottini, F., Orsi, D., Franceschi, V., & Fisicaro, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063062 · Cited by 13

A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model

Frise, R., Baillon, L., Zhou, J., Kugathasan, R., Peacock, T. P., Brown, J. C., Samnuan, K., McKay, P. F., Shattock, R. J., & Barclay, W. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.064 · Cited by 13

Development of a Low-Cost Pulse Oximeter for Taking Medical-Scientific Parameters to Monitor Remote Patients

Viciano-Tudela, S., Sendra, S., Lloret, J., Tomas, J., & Belda, J. (2022) · Electronics · doi:10.3390/electronics11193061 · Cited by 13

Infection of Bronchial Epithelial Cells by the Human Adenoviruses A12, B3, and C2 Differently Regulates the Innate Antiviral Effector APOBEC3B

Lejeune, N., Poulain, F., Willemart, K., Blockx, Z., Mathieu, S., & Gillet, N. A. (2021) · Journal of Virology · doi:10.1128/jvi.02413-20 · Cited by 12

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11

Structure Elucidation of Triterpenoid Saponins Found in an Immunoadjuvant Preparation of Quillaja brasiliensis Using Mass Spectrometry and 1H and 13C NMR Spectroscopy

Wallace, F., Fontana, C., Ferreira, F. A., & Olivaro, C. (2022) · Molecules · doi:10.3390/molecules27082402 · Cited by 13

Prediction of transport, deposition, and resultant immune response of nasal spray vaccine droplets using a CFPD-HCD model in a 6-year-old upper airway geometry to potentially prevent COVID-19

Hayati, H., Feng, Y., Chen, X., Kolewe, E. L., & Fromen, C. A. (2023) · Experimental and Computational Multiphase Flow · doi:10.1007/s42757-022-0145-7 · Cited by 12

Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein

Bonam, S. R., & Hu, H. (2023) · Zoonoses · doi:10.15212/zoonoses-2023-0003 · Cited by 12

Viral Vaccines and Current Status of Vaccine Developing Studies Against Novel SARS Coronavirus-2

Keşli, R. (2020) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2020.84755

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40

Phase III Vaccines for SARS-CoV-2: A Review of Development and Available Data

Ehsan, H. S. A., Sana, M. K., Sarwar, A., Hanif, N., & Khan, S. R. (2020) · Internal Medicine Review · doi:10.18103/imr.v6i5.905

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 80

Latest in COVID-19 Vaccine 'Candidates' Race

Atoum, M. F. M., Zreig, D. A., & Zreig, L. M. A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220818124416